Research ExplorerPublicationsHigh-dose chemotherapy followed by autologous stem cell tran...

High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review.

Standard

High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review. / Peinemann, Frank; Kröger, Nicolaus; Bartel, Carmen; Grouven, Ulrich; Pittler, Max; Erttmann, Rudolf; Kulig, Michael.

In: PLOS ONE, Vol. 6, No. 2, 2, 2011, p. 17127.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Peinemann, F, Kröger, N, Bartel, C, Grouven, U, Pittler, M, Erttmann, R & Kulig, M 2011, 'High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review.', PLOS ONE, vol. 6, no. 2, 2, pp. 17127. https://doi.org/10.1371/journal.pone.0017127

APA

Peinemann, F., Kröger, N., Bartel, C., Grouven, U., Pittler, M., Erttmann, R., & Kulig, M. (2011). High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review. PLOS ONE, 6(2), 17127. [2]. https://doi.org/10.1371/journal.pone.0017127

Vancouver

Peinemann F, Kröger N, Bartel C, Grouven U, Pittler M, Erttmann R et al. High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review. PLOS ONE. 2011;6(2):17127. 2. https://doi.org/10.1371/journal.pone.0017127

Bibtex

@article{b2615d379966449ab0fd3c71c2febacd,
title = "High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review.",
abstract = "Patients with metastatic rhabdomyosarcoma (RMS) have a poor prognosis. The aim of this systematic review is to investigate whether high-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (HSCT) in patients with metastatic RMS has additional benefit or harm compared to standard chemotherapy.",
keywords = "Adult, Humans, Adolescent, Young Adult, Treatment Outcome, Child, Prognosis, Combined Modality Therapy, Child, Preschool, Infant, Infant, Newborn, Neoplasm Metastasis, Hematopoietic Stem Cell Transplantation, Dose-Response Relationship, Drug, Transplantation, Autologous, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage, Rhabdomyosarcoma/diagnosis/mortality/pathology/*therapy, Adult, Humans, Adolescent, Young Adult, Treatment Outcome, Child, Prognosis, Combined Modality Therapy, Child, Preschool, Infant, Infant, Newborn, Neoplasm Metastasis, Hematopoietic Stem Cell Transplantation, Dose-Response Relationship, Drug, Transplantation, Autologous, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage, Rhabdomyosarcoma/diagnosis/mortality/pathology/*therapy",
author = "Frank Peinemann and Nicolaus Kr{\"o}ger and Carmen Bartel and Ulrich Grouven and Max Pittler and Rudolf Erttmann and Michael Kulig",
year = "2011",
doi = "10.1371/journal.pone.0017127",
language = "English",
volume = "6",
pages = "17127",
journal = "PLOS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

RIS

TY - JOUR

T1 - High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review.

AU - Peinemann, Frank

AU - Kröger, Nicolaus

AU - Bartel, Carmen

AU - Grouven, Ulrich

AU - Pittler, Max

AU - Erttmann, Rudolf

AU - Kulig, Michael

PY - 2011

Y1 - 2011

N2 - Patients with metastatic rhabdomyosarcoma (RMS) have a poor prognosis. The aim of this systematic review is to investigate whether high-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (HSCT) in patients with metastatic RMS has additional benefit or harm compared to standard chemotherapy.

AB - Patients with metastatic rhabdomyosarcoma (RMS) have a poor prognosis. The aim of this systematic review is to investigate whether high-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (HSCT) in patients with metastatic RMS has additional benefit or harm compared to standard chemotherapy.

KW - Adult

KW - Humans

KW - Adolescent

KW - Young Adult

KW - Treatment Outcome

KW - Child

KW - Prognosis

KW - Combined Modality Therapy

KW - Child, Preschool

KW - Infant

KW - Infant, Newborn

KW - Neoplasm Metastasis

KW - Hematopoietic Stem Cell Transplantation

KW - Dose-Response Relationship, Drug

KW - Transplantation, Autologous

KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage

KW - Rhabdomyosarcoma/diagnosis/mortality/pathology/therapy

KW - Adult

KW - Humans

KW - Adolescent

KW - Young Adult

KW - Treatment Outcome

KW - Child

KW - Prognosis

KW - Combined Modality Therapy

KW - Child, Preschool

KW - Infant

KW - Infant, Newborn

KW - Neoplasm Metastasis

KW - Hematopoietic Stem Cell Transplantation

KW - Dose-Response Relationship, Drug

KW - Transplantation, Autologous

KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage

KW - Rhabdomyosarcoma/diagnosis/mortality/pathology/therapy

U2 - 10.1371/journal.pone.0017127

DO - 10.1371/journal.pone.0017127

M3 - SCORING: Journal article

VL - 6

SP - 17127

JO - PLOS ONE

JF - PLOS ONE

SN - 1932-6203

IS - 2

M1 - 2

ER -